CancerSpot, Strand Life Sciences and Reliance Industries

Reliance Industries-powered Strand Life Sciences unveils CancerSpot test for early detection of multiple cancers
Strand Life Sciences, a subsidiary of Reliance Industries, has introduced CancerSpot, a blood-based test for early cancer detection. It employs methylation profiling technology to identify tumor DNA fragments from blood samples.
Reliance subsidiary Strand Life Sciences’ blood-based test to detect multiple cancers early-on
Strand Life Sciences launches CancerSpot, a blood-based test for early cancer detection, using advanced methylation profiling technology.
CancerSpot: A Breakthrough in Early Cancer Detection by Strand Life Sciences
Strand Life Sciences, a subsidiary of Reliance Industries, introduces CancerSpot, a new blood test for early cancer detection using advanced methylation profiling technology. Derived from Indian cohorts,
Strand Life Sciences, a Reliance subsidiary, Launches Pioneering Blood-based Test for Early Detection of Multiple Cancers
Leading genomics and bioinformatics company Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched a novel blood-based test for early detection of multiple cancers. Called CancerSpot,
Strand Life Sciences Launches Blood Test for Early Cancer Detection
Strand Life Sciences introduces CancerSpot, a blood-based test using methylation profiling for early detection of multiple cancers. The test offers a simple, non-invasive way to identify cancer tumor DNA fragments in blood.
Strand Life Sciences Launches Groundbreaking Cancer Detection Test
Strand Life Sciences introduces CancerSpot, a blood-based test using methylation profiling technology for early detection of multiple cancers. The test aims to address the growing cancer burden in India by offering transformative healthcare solutions.
Strand Life Sciences subsidiary of Reliance Life Sciences launches blood test for early detection of multiple cancers
Strand Life Sciences subsidiary of Reliance Life Sciences launches blood test for early detection of multiple cancers: Our Bureau, Bengaluru Monday, December 2, 2024, 14:40 Hrs [I
Genomic testing players like RIL's Strand eye tier-2, 3 markets as demand grows
Genomic testing involves analysing or sequencing a person’s DNA, to identify genetic changes that can help diagnose or screen ...
Health and Me on MSN2d
Researchers Launch CancerSpot-A Blood test That Could Detect Cancer Even Before Symptoms Appear
Strand Life Sciences has introduced CancerSpot, a blood-based test designed for the early detection of multiple cancers. This ...
moneycontrol.com2y
Strand Life Sciences
These advancements are customised to meet the unique requirements of the Indian population and provide unmatched precision, economy, and efficiency, according to a release by the company. Advisory ...